UCBB (US-China Biomedical Technology) Ending Cash Position : $0.14 Mil (As of May. 2019)

View and export this data going back to 2011. Start your Free Trial

What is US-China Biomedical Technology Ending Cash Position?

US-China Biomedical Technology's Ending Cash Position for the quarter that ended in May. 2019 was $0.14 Mil.

US-China Biomedical Technology's quarterly Ending Cash Position declined from Nov. 2018 ($0.21 Mil) to Feb. 2019 ($0.04 Mil) but then increased from Feb. 2019 ($0.04 Mil) to May. 2019 ($0.14 Mil).

US-China Biomedical Technology's annual Ending Cash Position increased from Feb. 2017 ($0.00 Mil) to Feb. 2018 ($0.06 Mil) but then declined from Feb. 2018 ($0.06 Mil) to Feb. 2019 ($0.04 Mil).

US-China Biomedical Technology Ending Cash Position Historical Data

The historical data trend for US-China Biomedical Technology's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US-China Biomedical Technology Ending Cash Position Chart

US-China Biomedical Technology Annual Data

Trend

Feb12

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Ending Cash Position

Get a 7-Day Free Trial

0.06

0.04

US-China Biomedical Technology Quarterly Data
	Aug14	Nov14	Feb15	May15	Aug15	Nov15	Feb16	May16	Aug16	Nov16	Feb17	May17	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19
Ending Cash Position	Get a 7-Day Free Trial															0.46	0.34	0.21	0.04	0.14

US-China Biomedical Technology Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

US-China Biomedical Technology's Ending Cash Position for the fiscal year that ended in Feb. 2019 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.057	+	-0.02
	=	0.04

US-China Biomedical Technology's Ending Cash Position for the quarter that ended in May. 2019 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.036	+	0.106
	=	0.14

US-China Biomedical Technology Ending Cash Position Related Terms

Thank you for viewing the detailed overview of US-China Biomedical Technology's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

US-China Biomedical Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US-China Biomedical Technology Inc (GREY:UCBB) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Park Plaza, Suite 400, Irvine, CA, USA, 92614

Website

https://www.ucbb.us

US-China Biomedical Technology Inc is an early stage biomedical technology and services company. It is engaged in the integration and development of synergistic relationships with high profiled doctors and hospitals that will act as a bridge for connecting patients and bio-technology advances in China with its network of US based doctors and hospitals. It provides services for moving patients from China to the US with an emphasis on the demographics including pre-screening and genetic testing for family members of cancer patients, patients suffering from Diabetes, and general medical services including preventative care and physicals.

US-China Biomedical Technology Headlines

No Headlines